Advances in understanding the immunopathogenic basis of ovarian cancer, and the immunopathologic basis for prior failures of immunotherapy for it and other carcinomas promises to afford novel treatment approaches with potential for significant efficacy, and reduced toxicities compared with cytotoxic agents. Drerup, Alvaro Padron, José Conejo-Garcia, Kruthi Murthy, Yang Liu, Mary Jo Turk, Kathrin Thedieck, Vincent Hurez, Rong Li, Ratna Vadlamudi, Tyler J. Studies extended to include tumor microenvironmental regulatory T cells Tregs which spawned many additional studies of their microenvironmental effects in cancer, among his most important contributions to date. Drerup, Aijie Liu, Vincent Hurez, Tyler J. There is a clear rationale to combine certain cytotoxic agents with immune therapies. Thus, the logistically simpler subcutaneous approach could be the best path forward, according to study investigators.
Treatment responses were positively correlated with irradiation doses and inversely correlated with tumor volumes. The median duration of progression-free survival was 21 months and median overall survival was 4 years. This concept forces us to rethink current approaches to harnessing potent, specific host immunity to battle cancer, most of which are based on the paradigm that inducing more antitumor immune cells alone is therapeutic. Immunotherapy for Ovarian Cancer Current Treatment Options in Oncology 2015 Jan;. These results illustrate the concept that treatments effects can be multi-faceted, which must be taken into account when designing combination therapies.
Tumors express antigens that should induce immune-mediated rejection, but spontaneous rejection of established tumors is rare. Of the remaining 10, 3 experienced chemotherapy-responsive recurrences and the rest remained disease-free. This trial has prompted further assessments. Thus, referral to early phase immunotherapy trials for ovarian cancer patients that fail conventional treatment merits consideration. Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. Farletuzumab alone was well-tolerated and did not augment toxicities of cytotoxics.
Only modest immunity was elicited by the vaccine antigen-specific T cell cytokines or tetramer labeling. Cancer Research, 2106;76 23 :6964-6974 Nikolaos Svoronos, Alfredo Perales-Puchalt, Michael J. This concept forces us to rethink current approaches to harnessing potent, specific host immunity to battle cancer, most of which are based on the paradigm that inducing more antitumor immune cells alone is therapeutic. In Press Aging Cell 2015 Jan;14 6 :945-956. Advances in understanding the immunopathogenic basis of ovarian cancer, and the immunopathologic basis for prior failures of immunotherapy for it and other carcinomas promises to afford novel treatment approaches with potential for significant efficacy, and reduced toxicities compared with cytotoxic agents. Wood, Andrea Boni, Brian T.
This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy. Although chemotherapy and surgical debulking can eliminate clinically apparent cancer, patients often succumb to chemotherapy-resistant tumor relapse within several years after initial remission. Cytotoxics were given every 21 days for 6 cycles, followed by weekly farletuzumab until progression. Immune effects included decreased vascular endothelial growth factor and statistically significant increases in lymphocytes and natural killer cells. Brumlik, Reinhard Waehler, David T.
However, as I discuss in this Personal Perspective, a newer paradigm predicts that reducing tumor-driven immune suppression will be clinically beneficial. Karagiannis Chapter 2: Biological Aspects and Clinical Applications of Serum Biomarkers in Ovarian Cancer Rouba Ali- Fehmi and Eman Abdulfatah Chapter 3: Ovarian Cancer Immunity: How Does Immune Suppression Grow Cancer? Immune stimulatory effects of rapamycin are mediated by stimulation of antitumor γδ T cells. Gupta, Gangadhara Sareddy, Srilakshmi Pandeswara, Shunhua Lao, Bin Yuan, Justin M. Sequential Intravesical Mitomycin plus Bacillus Calmette-Guerin for Non-Muscle Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial Clinical Cancer Research 2015 Jan;21:303-311. Thus, farletuzumab alone might be poorly effective, but combination with carboplatin plus a taxane could merit additional consideration in platinum sensitive first relapse. This protein inhibits anti-tumor T cells, protecting tumors from immune elimination. It involves group teaching of clinical service care provision to medical students, house officers and fellows in rural clinics in the San Antonio area, Rio Grande Valley, Haiti and the Dominican Republic.
This paper demonstrates in a pre-clinical model how combination immunotherapy could be better than individual immunotherapy agents to treat ovarian cancer, and how immunotherapy can be combined with a standard cytotoxic agent. Links from websites affiliated with The University of Texas Health Science Center at San Antonio's website uthscsa. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model Experimental Gerontology 2018 Jan;105:146-154. Grade 1—2 adverse events were noted in 80% of patients, with grade 3 fatigue reported in 2. Interferon-α is the principal type I interferon tested for human anti-cancer activity. Immune therapy has a sound theoretical basis for treating carcinomas generally, and for treating ovarian cancer in particular.
We also study age effects on immunity and immunotherapy, and immunopathogenesis of autoimmune disease. Biphasic rapamycin effects in lymphoma and carcinoma treatment Cancer Research 2017 Jan;77:520-531. Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. One patient had stable disease at 8 weeks whereas the others progressed. However, as I discuss in this Personal Perspective, a newer paradigm predicts that reducing tumor-driven immune suppression will be clinically beneficial. This is the first report showing that combination immunotherapy could improve clinical outcomes in ovarian cancer in human patients. The E-mail message field is required.
Most patients 82% were platinum-resistant or refractory, and heavily pre-treated. Consult a health care provider if you are in need of treatment. Description: 1 online resource Contents: Part 1. Linehan, Hanyu Liang, Terry Q. Nonetheless, anti-tumor antibodies were also generated.